ArticleOncotarget2017
Oncogene TUBA1C promotes migration and proliferation in hepatocellular carcinoma and predicts a poor prognosis.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- An externally validated lactylation-associated prognostic signature for overall survival prediction in lung adenocarcinoma identifiesTranslational cancer research · 2026Article
- Construction of a Prognostic Model and Subgroup Characteristics Related to Hypoxia-Immune Evasion in T Cells of Hepatocellular Carcinoma Based on Single-Cell and Bulk RNA Analysis.Journal of hepatocellular carcinoma · 2026Article
- Salivary Proteome Is Altered in Children With Small Area Thermal Burns.Proteomics. Clinical applications · 2025Article
- MicroRNA Regulatory Pattern in Diabetic Mouse Cortex at Different Stages Following Ischemic Stroke.Journal of molecular neuroscience : MN · 2024Article
- From single-cell to spatial transcriptomics: decoding the glioma stem cell niche and its clinical implications.Frontiers in immunology · 2024Article
- Identification and validation of microtubule depolymerizing agent, CYT997, as a potential drug candidate for hepatocellular carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2023Article
- Article
- TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.BMC cancer · 2023Article
- TUBA1C: a new potential target of LncRNA EGFR-AS1 promotes gastric cancer progression.BMC cancer · 2023Article
- Article
- Understanding molecular mechanisms and predicting phenotypic effects of pathogenic tubulin mutations.PLoS computational biology · 2022Article
- The oncogenic role of tubulin alpha-1c chain in human tumours.BMC cancer · 2022Article
- α1A and α1C form microtubules to display distinct properties mainly mediated by their C-terminal tails.Journal of molecular cell biology · 2022Article
- Comprehensive Multiomic Analysis Identified TUBA1C as a Potential Prognostic Biological Marker of Immune-Related Therapy in Pan-Cancer.Computational and mathematical methods in medicine · 2022Article
- In silico recognition of a prognostic signature in basal-like breast cancer patients.PloS one · 2022Article
- Role of germline variants in the metastasis of breast carcinomas.Oncotarget · 2022Article
- Cyanidin 3-glucoside modulated cell cycle progression in liver precancerous lesion,World journal of gastroenterology · 2021Article
- Prognostic biomarker TUBA1C is correlated to immune cell infiltration in the tumor microenvironment of lung adenocarcinoma.Cancer cell international · 2021Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognostic biomarkers and potential therapy targets are urgently needed in hepatocellular carcinoma (HCC). In this article, we report the expression of TUBA1C was significantly increased in HCC on mRNA and protein level, and this finding was further validated in another two independent datasets. Survival analysis was also implemented on these three datasets, and TUBA1C high expression group was detected to have relative shorter survival time. Furthermore, the metastatic ability is increased along with TUBA1C abundance, according to protein abundance evaluation of normal-tumor-portal vein tumor thrombus pairs, and mRNA comparison between metastasis-averse HCC and metastasis-incline HCC. Correlation analysis was implemented and TUBA1C expression was shown to be significantly associated with recurrence, embolus, and AFP level. Proliferation and migration assays following knock down of TUBA1C in two cell lines, HCCLM3 and PLC, revealed that down-regulation of TUBA1C significantly reduces proliferation and migration in HCC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.